CD262 Antibody, anti-human, REAfinity™
Synonyms: TNFRSF10B, DR5, KILLER, TRAIL-R2, TRICK2, TRICK2A, TRICK2B, TRICKB, ZTNFR9
RECOMBINANT
Clone:
REA1237 | DJR2-4
Type of antibody:
Primary antibodies, Recombinant antibodies
Isotype:
recombinant human IgG1
Applications:
FC Glossary
External link icon
Quality Assurance Certified ProductSatisfaction
guaranteed
more »
Select a conjugate:
Select a size:
Other sizes

Related products for CD262 Antibody, anti-human, REAfinity™

Flow cytometry applications
PE
PE-Vio 615
Vio Bright B515
Vio Bright V423
Vio Bright V600
Recommended dilution:
1:50
Remark:
Cells should be stained prior to fixation, if formaldehyde is used as a fixative.
Data source:
Miltenyi Biotec
Conjugate:
PE
Used products:
130-124-716, 130-124-721
Description:
BJ cells were stained with CD262 antibodies or with the corresponding REA control (S) antibodies (left peak) and analyzed by flow cytometry using the MACSQuant® Analyzer. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence or 4',6-diamidino-2-phenylindole (DAPI) fluorescence, as in the case of tandem conjugates.

Application image
Specifications for CD262 Antibody, anti-human, REAfinity™
Overview

Clone REA1237 binds to the human CD262 antigen, the Death Receptor 5 (DR5), member 10B of the TNF receptor superfamily (TNFRSF10B), also known as CD262, TRAIL-R2/ TRAILR2, TRICK2, KILLER, and ZTNFR9. Binding of “TNF-related apoptosis-inducing ligand” (TRAIL, TNFSF10, TL2, APO2L, Apo-2L) to DR5 induces apoptosis via the intracellular adaptor molecule FADD/MORT. The DR5 receptor is broadly expressed on many tumors and normal tissues. DR5 expression is upregulated by interferon-alpha, taxotere and paclitaxel, making DR5+ target cells more susceptible to NK cell mediated killing.

Additional information: Clone REA1237 displays negligible binding to Fc receptors.

Alternative names

TNFRSF10B, DR5, KILLER, TRAIL-R2, TRICK2, TRICK2A, TRICK2B, TRICKB, ZTNFR9

Detailed product information

Technical specifications

Clone
REA1237
Clonality
monoclonal
Isotype
recombinant human IgG1
Isotype control
REA Control Antibody (S), human IgG1
Host
human cell line
Type of antibody
Primary antibodies, Recombinant antibodies
Species reactivity
human
Antigen
CD262
Molecular mass of antigen [kDa]
42
Distribution of antigen
tumor cells, spleen, liver, prostate, heart, kidney, ovary
Entrez Gene ID

Recombinant antibodies at Miltenyi Biotec

As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.

The Miltenyi way of generating best-in-class antibodies and antibody conjugates

At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.

Infusing our unique expertise

Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.

Maximizing value for your research

By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:

reduce undesirable binding to Fc gamma receptors,

  • eliminate destabilizing amino acid motifs,
  • increase specific bonding affinity for stronger, more accurate targeting, and
  • optimize fluorochrome conjugation for brighter and clearer signals.

In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.

Better science with quality antibodies

Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).

Resources for CD262 Antibody, anti-human, REAfinity™
Certificates

To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.

Get certificate

Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.

Contact technical support

Citations for CD262 Antibody, anti-human, REAfinity™
Publications
  1. LaVallee, T. M. et al. (2003) 2-methoxyestradiol up-regulates death receptor 5 and induces apoptosis through activation of the extrinsic pathway. Cancer Res. 63 (2): 468-475
  2. Sato, K. et al. (2005) TRAIL-transduced dendritic cells protect mice from acute graft-versus-host disease and leukemia relapse. J Immunol 174 (7): 4025-4033
  3. Nimmanapalli, R. et al. (2001) Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 62 (2): 759-763

You have previously chosen International as your location.
What do you want to do?